Claims

Search Type State Status Topic Model Order Counting Over

As of snapshot 27745 under ledger-default@0.3.0.

Claim	Type	Assessment	Score	Review checks	References
In the phase 1 mRNA-1215 trial, antibody responses increased after the booster dose and remained elevated for at least one year.	QUANTITATIVE	Supported	0.8808	1 of 4	104
In a phase 1, first-in-human trial of mRNA-1215 in 40 healthy adults, no serious adverse events occurred during the study.	QUANTITATIVE	Supported	0.8808	1 of 4	92